HCWB HCW Biologics Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 14, 2026
$1,68
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$1,5052 haftanın en düşüğü
$29,2852 haftanın en yükseği
P/E (TTM)
-0.1
Hisse Başına Kâr (TTM)
$-13.98
Gelir (TTM)
$7M
rozetleriniz
52 Haftlık Aralık
$2–$29
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$30
P/E
-0.1
ROE
-151.4%
Net Kâr Marjı
-83.4%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
HCWB Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$1.68
P/E (TTM)
-0.1
Hisse Başına Kâr (TTM)
$-13.98
Gelir (TTM)
$7M
ROE (TTM)
-151.4%
D/E Borç/Özsermaye (MRQ)
0.9
52 Haftlık Aralık
$2–$29
HCWB Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 30 Haziran 2026 | 1-for-6 | Ters |
| 11 Nisan 2025 | 1-for-40 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$54.2K2020-12-31 → 2025-12-31
Hisse Başına Kâr$-10.632021-12-31 → 2025-12-31
Serbest Nakit Akışı$-13M2021-12-31 → 2025-12-31
Net kar marjı-83.4%2022-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | HCWB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -0.15Y ort. ≈-77.5 | ≈-77.5 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | HCWB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Brüt Kar Marjı (TTM) | 96.3%5Y ort. ≈28.9% | ≈28.9% | · | · | |
| Faaliyet Kâr Marjı (TTM) | -114.5%5Y ort. ≈-6637.1% | ≈-6637.1% | -869.3% | En üst düzey | |
| FAVÖK Marjı (TTM) | -105.5%5Y ort. ≈-6132.7% | ≈-6132.7% | -866.6% | En üst düzey | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | -14677.1%5Y ort. ≈-4237.0% | ≈-4237.0% | · | · | |
| Net Kâr Marjı (TTM) | -83.4%5Y ort. ≈-4237.0% | ≈-4237.0% | -862.3% | En üst düzey | |
| ROA (TTM) | -20.1%5Y ort. ≈-49.6% | ≈-49.6% | -125.6% | En üst düzey | |
| ROE (TTM) | -151.4%5Y ort. ≈-72.5% | ≈-72.5% | -294.8% | Zayıf | |
| ROIC | -137.5%5Y ort. ≈1572.2% | ≈1572.2% | · | · |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | HCWB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.95Y ort. ≈0.9 | ≈0.9 | 0.0 | Yüksek borç | |
| Cari Oran (MRQ) | 0.15Y ort. ≈7.3 | ≈7.3 | 2.0 | Düşük likidite | |
| Cari Oran (MRQ) | 0.05Y ort. ≈6.8 | ≈6.8 | 1.5 | Düşük likidite | |
| Interest Coverage (Faiz Karşılama Oranı) | -15.65Y ort. ≈-68.0 | ≈-68.0 | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | HCWB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | -97.9%5Y ort. ≈-55.1% | ≈-55.1% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -79.9% | · | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | -57.9% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | HCWB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.05Y ort. ≈0.1 | ≈0.1 | 0.0 | Zayıf | |
| Receivables Turnover (Alacak Devir Hızı) | 0.25Y ort. ≈9.0 | ≈9.0 | · | · | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.5K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-141.5%
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 14, 2026 | $-11.58 | $-2.02 | -473.4% |
| 31 Mart 2026 | May 14, 2026 | $2.22 | $-2.69 | 182.4% |
| 31 Aralık 2025 | $-18.36 | $-5.14 | -257.1% | |
| 30 Eylül 2025 | $-12.12 | $-14.08 | 13.9% | |
| 30 Haziran 2025 | $-6.48 | $11.02 | -158.8% | |
| 31 Aralık 2024 | $-3.20 | $3.67 | -187.1% | |
| 31 Aralık 2023 | $-12.00 | $-5.71 | -110.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $54.2K | $3M | $3M | $7M | $0 | $4M | |
| Cost of Revenue | $43.4K | $2M | $2M | $4M | $0 | · | |
| Gross Profit | $10.8K | $959.4K | $560.4K | $3M | $0 | · | |
| R&D Expense | $5M | $6M | $8M | $9M | $8M | $7M | |
| SG&A Expense | $8M | $7M | $7M | $8M | $5M | $3M | |
| Operating Expenses | $13M | $30M | $26M | $18M | $13M | $10M | |
| Operating Income | $-13M | $-29M | $-26M | $-15M | $-13M | $-6M | |
| Interest Expense | $845.1K | $654.3K | $283.0K | $126.7K | $0 | · | |
| Other Non-op | $0 | $-1M | · | · | · | · | |
| Pretax Income | $-8M | $-30M | $-25M | $-15M | $-13M | $-6M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-8M | $-30M | $-25M | $-15M | $-13M | $-6M | |
| EPS (Basic) | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 | · | |
| EPS (Diluted) | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 | · | |
| Shares (Basic) | 2,097,701 | 969,825 | 35,929,446 | 35,822,249 | 18,770,935 | · | |
| Shares (Diluted) | 2,097,701 | 969,825 | 35,929,446 | 35,822,249 | 18,770,935 | · | |
| EBITDA | $-12M | $-28M | $-25M | $-14M | $-13M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2M | $5M | $4M | $22M | $12M | $8M | |
| Short-term Investments | $0 | $0 | $0 | $10M | $25M | · | |
| Receivables | $32.2K | $582.2K | $2M | $417.7K | $133.0K | $2M | |
| Prepaid Expense | $222.2K | $328.2K | $1M | $1M | $2M | $538.3K | |
| Other Current Assets | $77.6K | $113.5K | $230.9K | $196.0K | $1M | $654.5K | |
| Current Assets | $2M | $6M | $6M | $34M | $40M | $12M | |
| PP&E (Net) | $21M | $23M | $20M | $11M | $1M | $2M | |
| PP&E (Gross) | $25M | $27M | $23M | $13M | $3M | $3M | |
| Accum. Depreciation | $4M | $4M | $3M | $2M | $2M | $1M | |
| Other Non-current Assets | $28.5K | $28.5K | $56.5K | $333.9K | $393.3K | $34.2K | |
| Total Assets | $25M | $30M | $29M | $47M | $54M | $15M | |
| Accounts Payable | $13M | $22M | $6M | $1M | $223.7K | $155.3K | |
| Short-term Debt | $7M | $6M | $0 | · | · | · | |
| Current Liabilities | $21M | $30M | $9M | $3M | $2M | $1M | |
| Capital Leases | · | · | · | $14.3K | · | · | |
| Deferred Tax | $24.9K | $40.9K | $146.9K | $0 | · | · | |
| Other Non-current Liabilities | $692.5K | · | · | · | · | · | |
| Total Liabilities | $22M | $37M | $15M | $9M | $2M | · | |
| Long-term Debt | $0 | $7M | $6M | $6M | $0 | · | |
| Total Debt | $7M | $6M | $119.4K | $38M | · | · | |
| Common Stock | $55 | $111 | $3.6K | $3.6K | $3.6K | · | |
| Paid-in Capital | $111M | $94M | $84M | $83M | $82M | $0 | |
| Retained Earnings | $-109M | $-101M | $-71M | $-46M | $-31M | $-17M | |
| Stockholders' Equity | $3M | $-7M | $13M | $37M | $51M | $-17M | |
| Liabilities + Equity | $25M | $30M | $29M | $47M | $54M | $15M |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $717.9K | $543.6K | $572.9K | |
| Stock-based Comp | $768.6K | $1M | $1M | $1M | $361.0K | $21.9K | |
| Other Non-cash | $-7M | $14M | $341.2K | $3M | $982.2K | · | |
| Operating Cash Flow | $-13M | $-14M | $-23M | $-10M | $-11M | $-10M | |
| CapEx | $0 | $261.6K | $6M | $10M | $47.3K | $186.7K | |
| Investing Cash Flow | $0 | $-261.6K | $4M | $15M | $-35M | $-186.7K | |
| Debt Issued | · | · | · | · | $0 | $563.6K | |
| Net Debt Issued | · | · | · | · | $0 | · | |
| Stock Issued | $5M | $6M | $23.7K | $15.8K | $29.5K | $9.9K | |
| Net Stock Activity | $5M | $6M | $23.7K | $15.8K | $29.5K | · | |
| Financing Cash Flow | $11M | $16M | $-14.5K | $6M | $49M | $12M | |
| Net Change in Cash | $-3M | $1M | $-19M | $11M | $3M | $1M | |
| Free Cash Flow | $-13M | $-14M | $-29M | $-21M | $-11M | · | |
| Levered FCF | $-14M | $-15M | · | $-21M | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 20.0% | 37.4% | 19.7% | 38.5% | · | · | |
| Operating Margin | -24270.7% | -1148.5% | -905.0% | -224.3% | · | · | |
| Net Margin | -14677.1% | -1169.7% | -879.5% | -221.7% | · | · | |
| Pretax Margin | -14677.1% | -1169.7% | -879.5% | -221.7% | · | · | |
| EBITDA Margin | -22349.8% | -1102.4% | -865.0% | -213.6% | · | · | |
| ROA | -29.1% | -102.2% | · | -29.7% | -37.3% | · | |
| ROE | -586.8% | 358.7% | · | -37.3% | -24.4% | · | |
| ROIC | -137.5% | 6472.1% | · | -19.9% | -26.1% | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.1 | 0.2 | · | 11.5 | 17.4 | · | |
| Quick Ratio | 0.1 | 0.2 | · | 11.0 | 15.9 | · | |
| Debt / Equity | 2.5 | -0.9 | · | 1.0 | · | · | |
| Interest Coverage | -15.6 | -46.7 | -90.9 | -119.0 | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | · | · | |
| Receivables Turnover | 0.2 | 2.4 | · | 24.4 | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue / Share | $0.03 | $0.07 | $0.08 | $0.19 | · | · | |
| Cash Flow / Share | $-6.38 | $-0.37 | $-0.63 | $-0.29 | · | · | |
| EPS (TTM) | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | -97.9% | -9.7% | -57.7% | · | · | · | |
| Revenue CAGR 3Y | -79.9% | · | -11.5% | · | · | · | |
| Revenue CAGR 5Y | -57.9% | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $54.2K | $3M | $3M | $7M | $0 | · | |
| Net Income TTM | $-8M | $-30M | $-25M | $-15M | $-13M | · | |
| P/E | -0.1 | -0.6 | -70.0 | -182.4 | -134.5 | · | |
| Earnings Yield | -1094.8% | -173.5% | -1.4% | -0.55% | -0.74% | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $151.7K | $6M | $27.0K | $15.6K | $6.5K | $5.1K | $394.8K | $426.4K | $618.9K | $1M | $1M | $853.1K | $622.8K | $41.9K | $1M | $2M | |
| Cost of Revenue | $229.5K | $11.1K | $21.6K | $12.5K | $5.2K | $4.1K | $315.8K | $341.1K | $438.4K | $512.0K | $1M | $678.3K | $502.4K | $29.4K | $1M | $1M | |
| Gross Profit | $-93.9K | $7M | $5.4K | $3.1K | $1.3K | $1.0K | $79.0K | $85.3K | $180.4K | $614.7K | $252.6K | $174.8K | $120.4K | $12.5K | $268.3K | $361.8K | |
| R&D Expense | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| SG&A Expense | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $564.4K | $2M | $2M | $3M | $3M | $2M | |
| Operating Expenses | $3M | $3M | $4M | $3M | $3M | $2M | $3M | $4M | $15M | $8M | $11M | $5M | $5M | $5M | $6M | $4M | |
| Operating Income | $-3M | $3M | $-4M | $-3M | $-3M | $-2M | $-3M | $-4M | $-15M | $-7M | $-11M | $-5M | $-5M | $-5M | $-6M | $-4M | |
| Interest Expense | $100.5K | $109.3K | $233.4K | $127.1K | $228.7K | $255.8K | $265.6K | $229.1K | $159.7K | $0 | $-1.4K | $95.5K | $95.5K | $93.4K | $94.5K | $32.2K | |
| Other Non-op | · | · | $0 | $0 | $0 | · | $0 | $0 | $-1M | · | · | $0 | $0 | · | · | · | |
| Pretax Income | $-5M | $4M | · | · | $-2M | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Income Tax | · | $330.2K | $0 | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $3M | $719.2K | $-5M | $-2M | $-2M | $-3M | $-4M | $-15M | $-7M | $-11M | $-5M | $-4M | $-5M | $-5M | $-4M | |
| EPS (Basic) | $-11.58 | $1.39 | $-1.77 | $-2.02 | $-40.72 | $-11.80 | $-10.47 | $-4.13 | $-16.16 | $-0.20 | $-0.30 | $-0.14 | $-0.12 | $-0.14 | $-0.15 | $-0.11 | |
| EPS (Diluted) | $-11.58 | $1.39 | $-1.77 | $-2.02 | $-40.72 | $-11.80 | $-10.47 | $-4.13 | $-16.16 | $-0.20 | $-0.30 | $-0.14 | $-0.12 | $-0.14 | $-0.15 | $-0.11 | |
| Shares (Basic) | 1,327,966 | 904,312 | · | 2,260,068 | 296,686 | 186,149 | · | 945,585 | 945,585 | 37,223,588 | · | 35,926,921 | 35,910,669 | 35,883,779 | · | 35,835,135 | |
| Shares (Diluted) | 1,327,966 | 904,312 | · | 2,260,068 | 296,686 | 186,149 | · | 945,585 | 945,585 | 37,223,588 | · | 35,926,921 | 35,910,669 | 35,883,779 | · | 35,835,135 | |
| EBITDA | $-3M | $3M | · | $-3M | $-3M | $-2M | · | $-4M | $-15M | $-7M | · | $-5M | $-5M | $-5M | · | $-4M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $741.3K | $1M | $2M | $1M | $2M | $1M | $5M | $998.2K | $1M | $4M | $4M | $11M | $7M | $18M | $22M | $26M | |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | $0 | $10M | $10M | $10M | $0 | |
| Receivables | $18.5K | $74.8K | $32.2K | $30.7K | $21.6K | $87.5K | $582.2K | $651.8K | $655.0K | $903.9K | $2M | $710.1K | $707.2K | $252.7K | $417.7K | $355.6K | |
| Prepaid Expense | $282.5K | $297.8K | $222.2K | $210.7K | $295.5K | $256.3K | $328.2K | $356.2K | $404.9K | $783.4K | $1M | $2M | $1M | $1M | $1M | $2M | |
| Other Current Assets | $97.7K | $119.8K | $77.6K | $250.3K | $141.0K | $443.3K | $113.5K | $88.1K | $164.6K | $187.3K | $230.9K | $174.9K | $327.1K | $317.0K | $196.0K | $205.9K | |
| Current Assets | $1M | $2M | $2M | $2M | $3M | $2M | $6M | $2M | $2M | $6M | $6M | $14M | $20M | $30M | $34M | $29M | |
| PP&E (Net) | $21M | $21M | $21M | $23M | $23M | $23M | $23M | $23M | $23M | $23M | $20M | $15M | $13M | $12M | $11M | $11M | |
| PP&E (Gross) | · | · | $25M | · | · | · | $27M | · | · | · | $23M | · | · | · | $13M | · | |
| Accum. Depreciation | · | · | $4M | · | · | · | $4M | · | · | · | $3M | · | · | · | $2M | · | |
| Other Non-current Assets | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $56.5K | $137.6K | $211.0K | $253.1K | $333.9K | $419.0K | |
| Total Assets | $27M | $27M | $25M | $25M | $29M | $26M | $30M | $27M | $27M | $30M | $29M | $36M | $39M | $44M | $47M | $51M | |
| Accounts Payable | $11M | $12M | $13M | $19M | $19M | $20M | $22M | $23M | $17M | $10M | $6M | $3M | $2M | $1M | $1M | $1M | |
| Short-term Debt | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | · | · | $0 | · | · | · | · | · | |
| Current Liabilities | $19M | $20M | $21M | $27M | $27M | $27M | $30M | $30M | $23M | $13M | $9M | $5M | $5M | $5M | $3M | $2M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | · | · | · | $7.5K | · | $56.7K | |
| Deferred Tax | · | · | $24.9K | · | · | · | $40.9K | · | · | · | $146.9K | · | · | · | $0 | · | |
| Other Non-current Liabilities | · | $692.5K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $19M | $22M | $22M | $28M | $29M | $35M | $37M | $37M | $33M | $22M | $15M | $12M | $11M | $11M | $9M | $9M | |
| Long-term Debt | · | · | $0 | $0 | $367.2K | $8M | $7M | $6M | $10M | $8M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Total Debt | $7M | $7M | · | $7M | $6M | $6M | · | $6M | · | · | · | $117.7K | $97.1K | $68.0K | · | · | |
| Common Stock | $161 | $112 | $328 | $262 | $215 | $4.5K | $111 | $3.8K | $3.8K | $3.8K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | |
| Paid-in Capital | · | · | $111M | $107M | $105M | $94M | $94M | $87M | $87M | $87M | $84M | $84M | $83M | $83M | $83M | $83M | |
| Retained Earnings | $-110M | $-105M | $-109M | $-109M | $-105M | $-103M | $-101M | $-97M | $-93M | $-78M | $-71M | $-60M | $-55M | $-51M | $-46M | $-40M | |
| Stockholders' Equity | $7M | $6M | $3M | $-2M | $-52.0K | $-9M | $-7M | $-10M | $-6M | $9M | $13M | $24M | $29M | $33M | $37M | $43M | |
| Liabilities + Equity | $27M | $27M | $25M | $25M | $29M | $26M | $30M | $27M | $27M | $30M | $29M | $36M | $39M | $44M | $47M | $51M |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $127.1K | $142.0K | $156.9K | $173.9K | $291.9K | $419.0K | $682.5K | $128.4K | $129.9K | $243.5K | $274.6K | $277.5K | $284.3K | $298.8K | $261.2K | $164.3K | |
| Stock-based Comp | $1.2K | $10.0K | $9.2K | $205.5K | $278.3K | $275.6K | $292.1K | $232.4K | $239.8K | $244.7K | $261.3K | $219.8K | $263.4K | $259.2K | $286.2K | $302.3K | |
| Other Non-cash | · | · | · | · | · | $-2M | · | · | · | $3M | · | · | · | $874.4K | · | · | |
| Operating Cash Flow | $-4M | $-2M | $-3M | $-3M | $-3M | $-4M | $-3M | $-3M | $-5M | $-4M | $-4M | $-6M | $-9M | $-4M | $-4M | $-2M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $113.4K | $37.1K | $-18.6K | $129.7K | $4M | $630.0K | $2M | $300.4K | $68.7K | $10M | |
| Investing Cash Flow | · | · | $0 | $0 | $0 | · | $-113.4K | $-37.1K | $18.6K | $-129.7K | $-4M | $9M | $-2M | $-300.4K | $-68.7K | $7M | |
| Stock Issued | · | · | $4M | $0 | $1M | $1.7K | $4M | $0 | $0 | $3M | $14.0K | $84 | $7.7K | $1.9K | $5.8K | $1.7K | |
| Net Stock Activity | · | · | · | · | · | $1.7K | · | · | · | $3M | · | · | · | $1.9K | · | · | |
| Financing Cash Flow | $3M | $851.6K | $4M | $2M | $5M | $-53.1K | $7M | $3M | $2M | $4M | $-15.2K | $-8.9K | $7.7K | $1.9K | $-39.8K | $6M | |
| Net Change in Cash | $-487.6K | $-723.6K | $855.6K | $-1M | $1M | $-4M | $4M | $-163.1K | $-3M | $489.0K | $-8M | $4M | $-11M | $-4M | $-4M | $11M | |
| Free Cash Flow | · | · | · | · | · | $-4M | · | · | · | $-4M | · | · | · | $-4M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 100.5% | · | 20.0% | 20.0% | 20.0% | · | 20.0% | 29.1% | 54.6% | · | 20.5% | 19.3% | 29.9% | · | 20.0% | |
| Operating Margin | · | 49.8% | · | -21095.3% | -52886.7% | -38811.5% | · | -865.4% | -2445.8% | -665.1% | · | -595.2% | -724.2% | -12798.9% | · | -222.2% | |
| Net Margin | · | · | · | -29183.2% | -29431.0% | -43373.6% | · | -915.1% | -2469.1% | -662.8% | · | -578.9% | -691.1% | -12106.8% | · | -216.4% | |
| Pretax Margin | · | 58.5% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | 52.0% | · | -21095.3% | -52886.7% | -30538.8% | · | -865.4% | -2445.8% | -643.5% | · | -595.2% | -724.2% | -12085.4% | · | -222.2% | |
| ROA | -18.8% | · | · | -17.5% | -6.9% | -7.8% | · | -12.6% | -46.1% | -20.2% | · | -11.4% | -9.9% | -10.7% | · | -7.3% | |
| ROE | -141.5% | · | · | 75.4% | 60.7% | -2460.8% | · | -56.2% | -137.1% | -36.1% | · | -14.9% | -11.5% | -12.4% | · | -8.1% | |
| ROIC | · | 23.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 2.6 | 4.4 | 6.6 | · | 12.5 | |
| Quick Ratio | 0.0 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.4 | · | 2.2 | 4.0 | 6.3 | · | 11.6 | |
| Debt / Equity | 0.9 | 1.1 | · | -3.2 | -123.6 | -0.7 | · | -0.6 | · | · | · | 0.0 | 0.0 | 0.0 | · | · | |
| Interest Coverage | -31.5 | 29.6 | · | -25.9 | -15.1 | -7.7 | · | -16.5 | -94.8 | · | · | -53.2 | -47.2 | -57.4 | · | · |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.2 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | 80.1 | · | 0.0 | 0.0 | 0.0 | · | 0.6 | 0.9 | 1.9 | · | 1.6 | 1.2 | 0.1 | · | 8.5 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | $7.19 | · | $0.01 | $0.00 | $0.00 | · | $0.01 | $0.02 | $0.03 | · | $0.02 | $0.02 | $0.00 | · | $0.05 | |
| Cash Flow / Share | · | $-1.74 | · | · | · | $-0.08 | · | · | · | $-0.10 | · | · | · | $-0.10 | · | · | |
| EPS (TTM) | $-13.98 | $-43.12 | · | $-65.01 | $-67.12 | $-42.56 | · | $-20.79 | $-16.80 | $-0.76 | · | $-0.55 | $-0.52 | $-0.50 | · | $-0.22 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $7M | $7M | · | $422.0K | $832.8K | $1M | · | $3M | $4M | $4M | · | $3M | $4M | $4M | · | $5M | |
| Net Income TTM | $-6M | $-2M | · | $-12M | $-11M | $-25M | · | $-37M | $-38M | $-27M | · | $-20M | $-19M | $-18M | · | $-13M | |
| P/E | -0.4 | -0.1 | · | -0.3 | -0.4 | -1.6 | · | -6.2 | -9.2 | -552.6 | · | -829.1 | -1001.5 | -672.5 | · | -2498.2 | |
| Earnings Yield | -280.2% | -1996.3% | · | -292.8% | -282.1% | -62.9% | · | -16.1% | -10.8% | -0.18% | · | -0.12% | -0.10% | -0.15% | · | -0.04% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $54.2K | $3M | $3M | $7M | $0 |
| Brüt Kâr Marjı % | 20.0% | 37.4% | 19.7% | 38.5% | · |
| Faaliyet Kâr Marjı % | -24270.7% | -1148.5% | -905.0% | -224.3% | · |
| Net Gelir | $-8M | $-30M | $-25M | $-15M | $-13M |
| Seyreltilmiş Hisse Başı Kâr | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 2.5 | -0.9 | · | 1.0 | · |
| Cari Oran | 0.1 | 0.2 | · | 11.5 | 17.4 |
| Cari Oran | 0.1 | 0.2 | · | 11.0 | 15.9 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-13M | $-14M | $-29M | $-21M | $-11M |
Kurumsal Sahipler (13F) 1 dosya · $15K toplam · Tarih itibarıyla 31 Aralık 2025
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
1
Tutulan Değer
$15K
Yeni pozisyonlar
7
Çıkan pozisyonlar
4
Kurumsal faaliyet — Q1 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 7 (+2 önceki Ç'ye göre) | 4 (+3 önceki Ç'ye göre) | 5 (+2 önceki Ç'ye göre) | 0 (-2 önceki Ç'ye göre) | +48K |
Q4 2025 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD GROUP INC | $14.979 | 15.426 | 100,00% | Hisse senetleri |
Aktivistler ve %5+ sahipler 2 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Hing C. Wong, Ph.D. ×2 başvurular | 13 Haziran 2025 | 23,38% | Değişiklik | · | SEC |
| Hing C. Wong (2) | 22 Kasım 2024 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 10 içeriden öğrenenler · 5 yöneticiler · 5 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Hing C. Wong, Ph.D. | Chief Executive Officer | 29 Temmuz 2026 P | 125.845 | 2 | 0 | $219.313 |
| Rebecca Byam | Chief Financial Officer | 22 Mayıs 2026 P | 57.245 | 1 | 0 | $19.929 |
| Lee Flowers | SVP of Business Development | 29 Temmuz 2026 P | 8.691 | 1 | 0 | $19.959 |
| Peter Rhode | Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations. | 11 Aralık 2023 M | 77.500 | 0 | 0 | $0 |
| Jin-An Jiao | VP of Development | 31 Mayıs 2022 M | 45.141 | 0 | 0 | $0 |
| Scott T Garrett | Yönetim kurulu üyesi | 29 Temmuz 2026 P | 41.644 | 2 | 0 | $269.069 |
| Gary M Winer | Yönetim kurulu üyesi | 16 Mayıs 2025 P | 4.075 | 0 | 0 | $0 |
| Rick S. Greene | Yönetim kurulu üyesi | 07 Mayıs 2025 P | 2.066 | 0 | 0 | $0 |
| Lisa M. Giles | Yönetim kurulu üyesi | 14 Haziran 2024 A | 35.815 | 0 | 0 | $0 |
| Medmira Capital Ltd. | 10% sahip | 15 Eylül 2021 J | 0 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 1 ETF tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 2.004 SH | 19 Ağustos 2026 | Günlük |
HCWB Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 7 analist
AL
Medyan hedef
$30.00
+1685,7%
2 28,6%
Güçlü Al
4 57,1%
Al
1 14,3%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
1 analist · 2026-10-01Ortalama hedef $30.00 +1685,7%
Düşük$30.00
Ortalama$30.00
Yüksek$30.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| HCWB | · | -0.1 | -97.9% | -14677.1% | -586.8% | 20.0% |
| DRMA | · | · | · | · | · | · |
| PMCB | $8M | -0.3 | · | · | -56.7% | · |
| GRI | $122.9K | -0.0 | · | · | -256.3% | · |
| MBIO | · | -2.5 | · | · | -30.9% | · |
| BRTX | $10M | -0.7 | -10.3% | -3959.4% | -547.6% | 93.4% |
| GOVX | $296.2K | · | -37.1% | -862.3% | -645.9% | · |
| VIVS | $4M | -0.3 | -9.0% | -10567.2% | -294.8% | · |
| APVO | $9M | -0.1 | · | · | -217.2% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 14, 2026